Advice
References
References
Cancer Research UK (2012) Breast cancer incidence statistics [online; accessed 11 January 2013]
Cancer Research UK (2012) In situ breast carcinoma incidence statistics [online; accessed 11 January 2013]
European Medicines Agency, Committee for Proprietary Medicinal Products (2000) Points to consider on switching between superiority and non-inferiority. CPMP/EWP/482/99
Ismael G, Hegg R, Muehlbauer S et al. (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology 13: 869–78
National Cancer Institute (2006) Cancer Therapy Evaluation Program Common terminology criteria for adverse events (v3.0) [online; accessed 18 January 2013]
National Collaborating Centre for Cancer (2009) Early and locally advanced breast cancer: diagnosis and treatment. NICE clinical guideline 80. Cardiff (UK)
National Institute for Health and Clinical Excellence (2012) Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. NICE technology appraisal guidance 257
National Institute for Health and Clinical Excellence (2009) Advanced breast cancer: diagnosis and treatment. NICE clinical guideline 81
National Institute for Health and Clinical Excellence (2009) Early and locally advanced breast cancer: diagnosis and treatment. NICE clinical guideline 80
National Institute for Health and Clinical Excellence (2006) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. NICE technology appraisal guidance 107
National Institute for Health and Clinical Excellence (2002) Guidance on the use of trastuzumab for the treatment of advanced breast cancer. NICE technology appraisal guidance 34
Perez-Garcia J, Cortes J (2012) A roadmap for accelerated drug approval in breast cancer? The Lancet Oncology 13: 850–1
Roche Products Limited (2012) Herceptin summary of product characteristics [online; accessed 18 January 2013]
US National Institutes of Health (2012) ClinicalTrials.gov Identifier: NCT01401166 [online; accessed 10 December 2012]
US National Institutes of Health (2012) ClinicalTrials.gov identifier: NCT01566721 [online; accessed 30 January 2013]